Patents Assigned to ZymoGenetics
  • Human transglutaminases
    Patent number: 5952011
    Abstract: Human prostatic and placental transglutaminases are identified and cloned. The human transglutaminases herein are useful for, inter alia, therapeutic wound repair, closure of skin grafts, stabilizing food preparations, and markers for identifying agents which act as agonists or antagonists of cellular apoptosis.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: September 14, 1999
    Assignee: ZymoGenetics, Inc.
    Inventors: Patrick J. O'Hara, Francis J. Grant, Paul O. Sheppard
  • Compositions and methods for treating bone deficit conditions
    Patent number: 5948776
    Abstract: Compounds containing two aromatic systems covalently linked through a linker containing one or more atoms, or "linker" defined as including a covalent bond per se so as to space the aromatic systems at a distance 1.5-15.ANG., are effective in treating conditions associated with bone deficits. The compounds can be administered to vertebrate subjects alone or in combination with additional agents that promote bone growth or that inhibit bone resorption. They can be screened for activity prior to administration by assessing their ability to effect the transcription of a reporter gene coupled to a promoter associated with a bone morphogenetic protein and/or their ability to stimulate calvarial growth in model animal systems.
    Type: Grant
    Filed: February 28, 1997
    Date of Patent: September 7, 1999
    Assignees: Zymogenetic, Inc., Osteoscreen, Inc.
    Inventors: Charles Petrie, Mark W. Orme, Nand Baindur, Kirk G. Robbins, Gregory R. Mundy
  • Class II cytokine receptor
    Patent number: 5945511
    Abstract: Novel receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise an extracellular domain of a cell-surface receptor that is expressed in kidneys, pancreas, prostate, adrenal cortex and nervous tissue. The polypeptides may be used within methods for detecting ligands that promote the proliferation and/or differentiation of these organs.
    Type: Grant
    Filed: October 2, 1997
    Date of Patent: August 31, 1999
    Assignee: ZymoGenetics, Inc.
    Inventors: Si Lok, Choon J. Kho, Anna C. Jelmberg, Robyn L Adams, Theodore E. Whitmore, Theresa M. Farrah
  • Compositions and methods for treating bone deficit conditions
    Patent number: 5939444
    Abstract: Compounds containing two aromatic systems covalently linked through a linker containing one or more atoms, or "linker" defined as including a covalent bond per se so as to space the aromatic systems at a distance 1.5-15 .ANG., are effective in treating conditions associated with bone deficits. The compounds can be administered to vertebrate subjects alone or in combination with additional agents that promote bone growth or that inhibit bone resorption. They can be screened for activity prior to administration by assessing their ability to effect the transcription of a reporter gene coupled to a promoter associated with a bone morphogenetic protein and/or their ability to stimulate calvarial growth in model animal systems.
    Type: Grant
    Filed: February 28, 1997
    Date of Patent: August 17, 1999
    Assignees: Zymogenetic, Inc., Osteoscreen, Inc.
    Inventors: Charles Petrie, Mark W. Orme, Nand Baindur, Kirk G. Robbins, Gregory R. Mundy
  • Transglutaminase cross-linkable polypeptides and methods relating thereto
    Patent number: 5939385
    Abstract: Polypeptides of from about 9-120 amino acid residues comprising a truncated segment of fibrinogen which may be flanked by elastomeric peptides, wherein the polypeptides are cross-linkable by a transglutaminase, homo- and copolymers containing such polypeptides are disclosed. The homo- and co-polymers disclosed herein are useful in tissue sealant and wound healing formulations.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 17, 1999
    Assignee: ZymoGenetics, Inc.
    Inventors: Virender Labroo, Sharon J. Busby
  • Human amyloid protein precursor homolog and kunitz-type inhibitor
    Patent number: 5935854
    Abstract: The present invention provides isolated DNA molecules comprising a DNA segment encoding a novel human amyloid protein precursor homologue and novel Kunitz-type inhibitors. Also provided are DNA constructs comprising a first DNA segment encoding a novel human amyloid protein precursor homologue or a novel Kunitz-type inhibitor wherein said first DNA segment is operably linked to additional DNA segments required for the expression for the first DNA segment, as well as host cells containing such DNA constructs and methods for producing proteins from the host cells.
    Type: Grant
    Filed: April 18, 1995
    Date of Patent: August 10, 1999
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Donald C. Foster, Kjeld E. Norris
  • Treatment agents and methods for treating type II diabetes and symptoms of type II diabetes
    Patent number: 5929058
    Abstract: Methods for treating non-insulin dependent Diabetes Mellitus (NIDDM), or Type II Diabetes, by administering a combination of treatment agents exhibiting glucocorticoid receptor type I agonist activity and glucocorticoid receptor type II antagonist activity are disclosed. Treatment agents having both glucocorticoid receptor type I agonist activity and glucocorticoid receptor type II antagonist activity are also disclosed. Screening methods for identifying compounds having both glucocorticoid receptor type I agonist activity and glucocorticoid receptor type II antagonist activity are disclosed.
    Type: Grant
    Filed: December 19, 1997
    Date of Patent: July 27, 1999
    Assignee: Zymogenetics, Inc.
    Inventor: Theresa A. Deisher
  • Hematopoietic cytokine receptor
    Patent number: 5925735
    Abstract: Novel receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise an extracellular ligand-binding domain of a cell-surface receptor that is expressed at high levels in lymphoid tissue, including B-cells and T-cells. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo.
    Type: Grant
    Filed: May 6, 1998
    Date of Patent: July 20, 1999
    Assignee: ZymoGenetics, Inc.
    Inventors: James W. Baumgartner, Donald C. Foster, Frank J. Grant, Cindy A. Sprecher
  • Methods for treating bone deficit conditions with benzothiazole
    Patent number: 5922753
    Abstract: Compounds containing two aromatic systems covalently linked through a linker containing one or more atoms, or "linker" defined as including a covalent bond per se so as to space the aromatic systems at a distance 1.5-15 .ANG., are effective in treating conditions associated with bone deficits. The compounds can be administered to vertebrate subjects alone or in combination with additional agents that promote bone growth or that inhibit bone resorption. They can be screened for activity prior to administration by assessing their ability to effect the transcription of a reporter gene coupled to a promoter associated with a bone morphogenetic protein and/or their ability to stimulate calvarial growth in model animal systems.
    Type: Grant
    Filed: February 28, 1997
    Date of Patent: July 13, 1999
    Assignees: Zymogenetics, Inc., OsteoScreen, Inc., University of Texas at Austin
    Inventors: Charles Petrie, Mark W. Orme, Nand Baindur, Kirk G. Robbins, Laurence H. Hurley, Sean M. Kerwin, Gregory R. Mundy
  • Compositions and methods for treating bone deficit conditions
    Patent number: 5919808
    Abstract: Compounds containing two aromatic systems covalently linked through a linker containing one or more atoms, or "linker" defined as including a covalent bond per se so as to space the aromatic systems at a distance 1.5-15.ANG., are effective in treating conditions associated with bone deficits. The compounds can be administered to vertebrate subjects alone or in combination with additional agents that promote bone growth or that inhibit bone resorption. They can be screened for activity prior to administration by assessing their ability to effect the transcription of a reporter gene coupled to a promoter associated with a bone morphogenetic protein and/or their ability to stimulate calvarial growth in model animal systems.
    Type: Grant
    Filed: February 28, 1997
    Date of Patent: July 6, 1999
    Assignees: Zymogenetics, Inc., Osteoscreen, Inc.
    Inventors: Charles Petrie, Mark W. Orme, Nand Baindur, Kirk G. Robbins, Maria Kontoyianni, Gregory R. Mundy
  • Method of detecting glucagon receptor antagonists
    Patent number: 5919635
    Abstract: The present invention provides isolated DNA molecules comprising a DNA segment encoding a glucagon receptor. Also provided are DNA constructs comprising a first DNA segment encoding a glucagon receptor operably linked to additional DNA segments required for the expression of the first DNA segment, as well as host cells containing such DNA constructs.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: July 6, 1999
    Assignee: ZymoGenetics, Inc.
    Inventors: Wayne R. Kindsvogel, Laura J. Jelinek, Paul O. Sheppard, Francis J. Grant, Joseph L. Kuijper, Donald C. Foster, Si Lok, Patrick J. O'Hara
  • Human Kunitz-type inhibitors and compositions thereof
    Patent number: 5914315
    Abstract: The present invention provides isolated DNA molecules comprising a DNA segment encoding novel human Kunitz-type inhibitors. Also provided are DNA constructs comprising a first DNA segment encoding a novel human Kunitz-type inhibitor wherein first DNA segment is operably linked to additional DNA segments required for the expression for the first DNA segment, as well as host cells containing such DNA constructs and methods for producing proteins from the host cells.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: June 22, 1999
    Assignees: Zymogenetics, Inc., University of New Mexico
    Inventors: Cindy A. Sprecher, Walt Kisiel, Donald C. Foster
  • Protein C production in non-human transgenic mammals
    Patent number: 5905185
    Abstract: Methods for producing protein C in transgenic non-human mammals are disclosed. The protein C is modified at the two-chain cleavage site between the light and heavy chains of protein C from Lys-Arg to R.sub.1 -R.sub.2 -R.sub.3 -R.sub.4 where R.sub.1 through R.sub.4 are individually Arg or Lys. DNA segments encoding modified protein C are introduced into the germ line of a non-human mammals, and the mammal or its female progeny produces milk containing protein C expressed from the introduced DNA segments. The protein C expressed from the introduced DNA segments has anticoagulant activity when activated. Non-human mammalian embryos and transgenic non-human mammals carrying DNA segments encoding heterologous protein C are also disclosed.
    Type: Grant
    Filed: November 26, 1996
    Date of Patent: May 18, 1999
    Assignees: PPL Therapeutics, ZymoGenetics, Inc.
    Inventors: Ian Garner, Ian R. Cottingham, Simon M. Temperley, Donald C. Foster, Cindy A. Sprecher, Donna E. Prunkard
  • Protease resistant PDGF and methods of use
    Patent number: 5905142
    Abstract: PDGF B-chain polypeptides characterized by the substitution or deletion of a lysine or arginine residue at position 27, 28, 32, 79, 80 or 81 of native B-chain are disclosed. Also disclosed are PDGF-like proteins containing the B-chain polypeptides. The polypeptides and proteins may be produced through the use of cultured cells transfected or transformed to express DNA molecules that encode the polypeptides. The PDGF-like proteins are useful as components of cell culture media and for accelerating the healing of wounds.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: May 18, 1999
    Assignee: ZymoGenetics, Inc.
    Inventor: Mark J. Murray
  • DNA molecules encoding PDGF molecules having protease resistant basic cleavage sites
    Patent number: 5895755
    Abstract: PDGF B-chain polypeptides characterized by the substitution or deletion of a lysine or arginine residue at position 27, 28, 32, 79, 80 or 81 of native B-chain are disclosed. Also disclosed are PDGF-like proteins containing the B-chain polypeptides. The polypeptides and proteins may be produced through the use of cultured cells transfected or transformed to express DNA molecules that encode the polypeptides. The PDGF-like proteins are useful as components of cell culture media and for accelerating the healing of wounds.
    Type: Grant
    Filed: September 9, 1994
    Date of Patent: April 20, 1999
    Assignee: ZymoGenetics, Inc.
    Inventor: Mark J. Murray
  • Combinatorial non-peptide libraries
    Patent number: 5891737
    Abstract: Predetermined combinatorial libraries of non-peptide compounds are disclosed. Compounds useful for generating such libraries are also disclosed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 6, 1999
    Assignee: ZymoGenetics, Inc.
    Inventors: Nand Baindur, Virender M. Labroo
  • Compositions and methods for producing heterologous polypeptides in Pichia methanolica
    Patent number: 5888768
    Abstract: DNA constructs, Pichia methanolica cells, and methods for producing polypeptides using the DNA constructs and cells are disclosed. The DNA constructs comprise a transcription promoter of a Pichia methanolica gene, a DNA segment encoding a polypeptide heterologous to P. methanolica, a transcription terminator of a P. methanolica gene, and a selectable marker. P. methanolica cells containing the DNA constructs are used within methods for producing polypeptides heterologous to P. methanolica. DNA molecules comprising transcription promoters of P. methanolica genes are also disclosed.
    Type: Grant
    Filed: September 18, 1997
    Date of Patent: March 30, 1999
    Assignee: ZymoGenetics, Inc.
    Inventor: Christopher K. Raymond
  • Stable DNA constructs
    Patent number: 5871957
    Abstract: Methods are provided for producing protein products in host cells and for selecting transformed cells comprising the step of transforming the host cell with a DNA molecule comprising a gene which complements a deficiency in the host cell. The host cell is s strain having a deficiency in a function necessary for normal cell growth. The gene in the DNA molecule, such as a plasmid, which complements the deficiency serves as a selection marker whereby the growth conditions for selection may comprise a conventional complex medium.
    Type: Grant
    Filed: August 22, 1994
    Date of Patent: February 16, 1999
    Assignee: ZymoGenetics, Inc.
    Inventors: Glenn H. Kawasaki, Leslie Bell
  • G protein coupled glutamate receptors
    Patent number: 5869609
    Abstract: Mammalian G protein coupled glutamate receptors are identified, isolated and purified. The receptors have been cloned, sequenced and expressed by recombinant means. The receptors and antibodies thereby may be used to identify agonists and antagonists of G protein coupled glutamate receptor mediated neuronal excitation, as well as in methods of diagnosis.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: February 9, 1999
    Assignees: Zymogenetics, Inc., The Board of Regents of the University of Washington
    Inventors: Eileen Ranae Mulvihill, Frederick Stamner Hagen, Khaled M. Houamed, Wolfhard Almers
  • Modified Factor VII
    Patent number: 5861374
    Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modification renders Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.
    Type: Grant
    Filed: February 12, 1996
    Date of Patent: January 19, 1999
    Assignees: Novo Nordisk A/S, ZymoGenetics, Inc.
    Inventors: Kathleen L Berkner, Lars Christian Petersen, Charles E. Hart